Related Experiment Videos
ETC-588 (Pfizer).
1Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. s.doggrell@xtra.co.nz
Current Opinion in Investigational Drugs (London, England : 2000)
|October 27, 2004
Summary
Pfizer is developing ETC-588 for acute ischemia treatment in atherosclerosis patients. Phase II trials for acute coronary syndrome are complete, advancing this potential therapy.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Atherosclerosis is a leading cause of ischemic events.
- Acute coronary syndrome requires effective and rapid treatment options.
Purpose of the Study:
- To evaluate the potential of ETC-588 as an acute treatment for ischemia.
- To assess ETC-588 in patients experiencing acute coronary syndrome.
Main Methods:
- Pfizer is developing ETC-588.
- Phase II clinical trials were conducted.
- Patient enrollment for phase II trials is complete.
Main Results:
- Enrollment in phase II trials is complete, indicating progress in evaluation.
- Data from these trials will inform the efficacy and safety of ETC-588.
Conclusions:
- ETC-588 shows promise as a potential acute treatment for atherosclerosis-related ischemia.
- Further results from phase II trials are anticipated to guide future development.